Adiponectin Reduces Glomerular Endothelial Glycocalyx Disruption and Restores Glomerular Barrier Function in a Mouse Model of Type 2 Diabetes
Diabetes · 2024
DOI: 10.2337/db23-0455 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, 2024. Verfasst von Sarah Fawaz und 12 weiteren Autor:innen. Beteiligte Einrichtung: Bristol Renal, Bristol Medical School, Translational Health Sciences, University of Bristol, Bristol, U.K. Hauptthemen laut MEDLINE: Glycocalyx, Adiponectin, Diabetes Mellitus, Type 2, Kidney Glomerulus. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: British Heart Foundation, MRC confidence in concepts, Biomarker Enterprise to Attack Diabetic Kidney Disease (BEAt-DKD) consortium.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Adiponectin has vascular anti-inflammatory and protective effects. Although adiponectin protects against the development of albuminuria, historically, the focus has been on podocyte protection within the glomerular filtration barrier (GFB). The first barrier to albumin in the GFB is the endothelial glycocalyx (eGlx), a surface gel-like barrier covering glomerular endothelial cells (GEnCs). In diabetes, eGlx dysfunction occurs before podocyte damage; hence, we hypothesized that adiponectin could protect from eGlx damage to prevent early vascular damage in diabetic kidney disease (DKD). Globular adiponectin (gAd) activated AMPK signaling in human GEnCs through AdipoR1. It significantly reduced eGlx shedding and the tumor necrosis factor-α (TNF-α)–mediated increase in syndecan-4 (SDC4) and MMP2 mRNA expression in GEnCs in vitro. It protected against increased TNF-α mRNA expression in glomeruli isolated from db/db mice and against expression of genes associated with glycocalyx shedding (namely, SDC4, MMP2, and MMP9). In addition, gAd protected against increased glomerular albumin permeability (Ps’alb) in glomeruli isolated from db/db mice when administered intraperitoneally and when applied directly to glomeruli (ex vivo). Ps’alb was inversely correlated with eGlx depth in vivo. In summary, adiponectin restored eGlx depth, which was correlated with improved glomerular barrier function, in diabetes. Article Highlights
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Bristol Renal, Bristol Medical School, Translational Health Sciences, University of Bristol, Bristol, U.K.
ORCID-Profile: Yan Qiu, Monica Gamez, Rebecca R Foster
Förderung
- British Heart Foundation
- MRC confidence in concepts
- Biomarker Enterprise to Attack Diabetic Kidney Disease (BEAt-DKD) consortium
- David Telling Charitable Trust
- Diabetes UK
- Kidney Research UK
- Wellcome Trust Partnership Award Fellowship
Zitieren
APA
Fawaz, S., Martin Alonso, A., Qiu, Y., Ramnath, R., Stowell-Connolly, H., Gamez, M., May, C., Down, C., Coward, R. J., Butler, M. J., Welsh, G. I., Satchell, S. C., & Foster, R. R. (2024). Adiponectin Reduces Glomerular Endothelial Glycocalyx Disruption and Restores Glomerular Barrier Function in a Mouse Model of Type 2 Diabetes. Diabetes. https://doi.org/10.2337/db23-0455
Vancouver
Fawaz S, Martin Alonso A, Qiu Y, Ramnath R, Stowell-Connolly H, Gamez M, et al. Adiponectin Reduces Glomerular Endothelial Glycocalyx Disruption and Restores Glomerular Barrier Function in a Mouse Model of Type 2 Diabetes. Diabetes. 2024. doi:10.2337/db23-0455
BibTeX
@article{Fawaz2024,
author = {Fawaz, Sarah and Martin Alonso, Aldara and Qiu, Yan and Ramnath, Raina and Stowell-Connolly, Holly and Gamez, Monica and May, Carl and Down, Colin and Coward, Richard J and Butler, Matthew J and Welsh, Gavin I and Satchell, Simon C and Foster, Rebecca R},
title = {Adiponectin Reduces Glomerular Endothelial Glycocalyx Disruption and Restores Glomerular Barrier Function in a Mouse Model of Type 2 Diabetes},
journal = {Diabetes},
year = {2024},
doi = {10.2337/db23-0455}
}
EUVIMED